OMERS ADMINISTRATION Corp Makes New Investment in Stoke Therapeutics, Inc. $STOK

OMERS ADMINISTRATION Corp bought a new position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 30,000 shares of the company’s stock, valued at approximately $982,000.

A number of other large investors have also made changes to their positions in the stock. Quantbot Technologies LP acquired a new stake in shares of Stoke Therapeutics in the second quarter valued at approximately $34,000. E Fund Management Co. Ltd. purchased a new position in Stoke Therapeutics during the second quarter worth approximately $202,000. BlackRock Inc. acquired a new position in Stoke Therapeutics during the second quarter worth $192,307,000. Deutsche Bank AG purchased a new stake in Stoke Therapeutics in the 2nd quarter valued at $1,891,000. Finally, Bank of New York Mellon Corp purchased a new stake in Stoke Therapeutics in the 2nd quarter valued at $5,375,000.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on STOK shares. Wedbush lifted their price target on Stoke Therapeutics from $38.00 to $40.00 and gave the stock an “outperform” rating in a report on Tuesday, August 4th. BTIG Research restated a “buy” rating and set a $39.00 price objective on shares of Stoke Therapeutics in a research report on Monday, May 11th. Guggenheim reaffirmed a “buy” rating and set a $60.00 target price on shares of Stoke Therapeutics in a research note on Tuesday, August 4th. Canaccord Genuity Group decreased their target price on shares of Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating on the stock in a report on Tuesday, August 4th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Stoke Therapeutics in a research note on Friday, August 21st. They issued an “overweight” rating and a $40.00 price target for the company. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $44.25.

Stoke Therapeutics Trading Down 1.5%

STOK stock opened at $32.59 on Friday. The company has a market capitalization of $2.10 billion, a PE ratio of -9.76 and a beta of 1.20. Stoke Therapeutics, Inc. has a 12-month low of $18.80 and a 12-month high of $40.22. The business’s fifty day moving average price is $31.21 and its 200 day moving average price is $32.26.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Monday, August 3rd. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). The firm had revenue of $9.32 million for the quarter, compared to analysts’ expectations of $4.89 million. Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. Research analysts predict that Stoke Therapeutics, Inc. will post -3.52 EPS for the current fiscal year.

Insider Transactions at Stoke Therapeutics

In related news, Director Edward M. Md Kaye sold 12,567 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $32.03, for a total value of $402,521.01. Following the completion of the transaction, the director owned 124,557 shares in the company, valued at approximately $3,989,560.71. The trade was a 9.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Jonathan Allan sold 2,861 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total transaction of $91,637.83. Following the sale, the general counsel directly owned 21,225 shares in the company, valued at approximately $679,836.75. The trade was a 11.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 30,623 shares of company stock valued at $953,765. 9.60% of the stock is currently owned by corporate insiders.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.